Testing mitizodone tablets for major depression symptoms
Part of Mental health clinical trials.
This trial studies whether mitizodone phosphate tablets can improve symptoms of major depressive disorder (MDD). It also checks the treatment’s safety, including mood and physical health effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have major depression as your main diagnosis, confirmed by DSM-5 criteria
- Your depression symptom score (MADRS) is 26 or higher at screening and start
- Your overall illness severity (CGI-S) is 4 or higher at screening and start
- You do NOT have psychotic depression, bipolar disorder, schizophrenia, or a past/present substance use problem
- You have no recent antidepressants/antipsychotics and no fluoxetine in the last 4 weeks
- You should not have serious heart, liver, kidney, nerve, blood, or endocrine problems, or certain eye conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach to treating major depressive disorder using assessments and brain imaging to match you with the best therapy. It aims to improve outcomes by tailoring care to your specific needs.
This trial tests an investigational medication called ammoxetine for people with moderate to severe depression. It aims to see if the drug can reduce depressive symptoms and is for those who haven't had success with certain other antidepressants.
This study tests an experimental oral pill called azetukalner against a placebo to see if it safely reduces symptoms of major depressive disorder. It is for adults who are currently in a depressive episode lasting 6 weeks to 2 years and have not already tried multiple antidepressants that failed.
This study tests whether zelquistinel, an investigational drug, can reduce symptoms of major depressive disorder (a type of clinical depression). It is for people who are currently experiencing a moderate to severe depressive episode and are not taking other antidepressants.
This study tests a new oral medication called Zelquistinel (taken as a tablet) against a placebo for treating major depressive disorder. Researchers want to see if it can reduce depression symptoms, especially when other antidepressants haven't been tried or haven't worked.
This Phase 2 trial tests whether an NMDA-targeted treatment can improve symptoms of major depressive disorder (MDD). You may be able to join if your depression diagnosis and symptom score fit, and you meet several safety and study-following requirements.
Hear when a new Depressive Disorder, Major trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.